MELBOURNE, Australia & WASHINGTON--(BUSINESS WIRE)--Anadis Ltd. (ASX:ANX; OTC: ANDIY) an Australian biopharmaceutical company announced today the in-licensing of GastroGard-R, an all-natural orally administered formulation containing specific antibodies proven to reduce rotavirus virus diarrhea in young children. The license allows Anadis to exclusively supply humanitarian agencies worldwide as well as to enter large national markets including India, Korea, Indonesia and Australia, with other countries expected to be added based on demand. GastroGard-R is positioned to complement global rotavirus virus vaccine initiatives and reduces overall morbidity and mortality from this terrible disease. The announcement was made at the Partnering for Global Health Forum 2008 (http://pgh.bio.org) being held in Washington D.C.
